{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:13:41Z","timestamp":1758759221412,"version":"3.44.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-025-01013-1","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T12:23:35Z","timestamp":1751027015000},"page":"740-745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reduction of polycystic kidney and liver volumes in a patient with tolvaptan-resistant autosomal dominant polycystic kidney disease and acromegaly during lanreotide therapy"],"prefix":"10.1007","volume":"14","author":[{"given":"Shun","family":"Takenaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9486-9071","authenticated-orcid":false,"given":"Fumihiko","family":"Hattanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Watanabe-Kusunoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daigo","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiraku","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Amengual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"issue":"9569","key":"1013_CR1","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287\u2013301.","journal-title":"Lancet"},{"issue":"4","key":"1013_CR2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10157-011-0428-y","volume":"15","author":"S Tokiwa","year":"2011","unstructured":"Tokiwa S, Muto S, China T, Horie S. The relationship between renal volume and renal function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2011;15(4):539\u201345.","journal-title":"Clin Exp Nephrol"},{"issue":"10","key":"1013_CR3","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone 2nd","year":"2003","unstructured":"Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9(10):1323\u20136.","journal-title":"Nat Med"},{"issue":"1","key":"1013_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","volume":"40","author":"MR Gadelha","year":"2019","unstructured":"Gadelha MR, Kasuki L, Lim DST, Fleseriu M. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. 2019;40(1):268\u2013332.","journal-title":"Endocr Rev"},{"issue":"4","key":"1013_CR5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, et al. Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord. 2020;21(4):667\u201378.","journal-title":"Rev Endocr Metab Disord"},{"issue":"2S","key":"1013_CR6","first-page":"S1","volume":"107","author":"Kidney Disease: Improving Global Outcomes AWG","year":"2025","unstructured":"Kidney Disease: Improving Global Outcomes AWG. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD). Kidney Int. 2025;107(2S):S1\u2013239.","journal-title":"Kidney Int"},{"issue":"9","key":"1013_CR7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552\u201361.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"1013_CR8","first-page":"1323","volume":"77","author":"JC Reubi","year":"1993","unstructured":"Reubi JC, Horisberger U, Studer UE, Waser B, Laissue JA. Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta. J Clin Endocrinol Metab. 1993;77(5):1323\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1013_CR9","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1056\/NEJM199601253340408","volume":"334","author":"SW Lamberts","year":"1996","unstructured":"Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996;334(4):246\u201354.","journal-title":"N Engl J Med"},{"issue":"2","key":"1013_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.ki.5002229","volume":"72","author":"E Parker","year":"2007","unstructured":"Parker E, Newby LJ, Sharpe CC, Rossetti S, Streets AJ, Harris PC, et al. Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras\/Raf signalling system. Kidney Int. 2007;72(2):157\u201365.","journal-title":"Kidney Int"},{"issue":"9","key":"1013_CR11","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1016\/j.ekir.2021.06.033","volume":"6","author":"S Makabe","year":"2021","unstructured":"Makabe S, Manabe S, Kataoka H, Akihisa T, Yoshida R, Ushio Y, et al. Urinary aquaporin 2 as a potential indicator predicting tolvaptan response in patients with ADPKD. Kidney Int Rep. 2021;6(9):2436\u201344.","journal-title":"Kidney Int Rep"},{"issue":"13","key":"1013_CR12","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.2169\/internalmedicine.55.6560","volume":"55","author":"M Yamamoto","year":"2016","unstructured":"Yamamoto M, Matsumoto R, Fukuoka H, Iguchi G, Takahashi M, Nishizawa H, et al. Prevalence of simple renal cysts in acromegaly. Intern Med. 2016;55(13):1685\u201390.","journal-title":"Intern Med"},{"issue":"4","key":"1013_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/EJE-16-0242","volume":"175","author":"S Fujio","year":"2016","unstructured":"Fujio S, Takano K, Arimura H, Habu M, Bohara M, Hirano H, et al. Treatable glomerular hyperfiltration in patients with active acromegaly. Eur J Endocrinol. 2016;175(4):325\u201333.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"1013_CR14","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/j.1365-2362.1992.tb01496.x","volume":"22","author":"RP Dullaart","year":"1992","unstructured":"Dullaart RP, Meijer S, Marbach P, Sluiter WJ. Effect of a somatostatin analogue, octreotide, on renal haemodynamics and albuminuria in acromegalic patients. Eur J Clin Invest. 1992;22(7):494\u2013502.","journal-title":"Eur J Clin Invest"},{"issue":"(25\u201326)","key":"1013_CR15","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1024\/0369-8394.91.25.1123","volume":"91","author":"R Fajfr","year":"2002","unstructured":"Fajfr R, M\u00fcller B, Diem P. Hypophyseal incidentaloma in a patient with autosomal dominant polycystic kidney disease. Praxis (Bern 1994). 2002;91((25\u201326)):1123\u20136.","journal-title":"Praxis (Bern 1994)"},{"issue":"1","key":"1013_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","volume":"68","author":"P Ruggenenti","year":"2005","unstructured":"Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int. 2005;68(1):206\u201316.","journal-title":"Kidney Int"},{"key":"1013_CR17","unstructured":"Kannabiran M, Singh V, Grewal S. Acromegaly presenting as psychotic disorder in a patient with familial autosomal dominant polycystic kidney disease. Ger J Psychiatry. 2006; 9:136\u2013138."},{"issue":"3","key":"1013_CR18","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s11102-011-0325-0","volume":"15","author":"LV Syro","year":"2012","unstructured":"Syro LV, Sundsbak JL, Scheithauer BW, Toledo RA, Camargo M, Heyer CM, et al. Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation. Pituitary. 2012;15(3):342\u20139.","journal-title":"Pituitary"},{"issue":"5","key":"1013_CR19","first-page":"e302","volume":"5","author":"S Mangaraj","year":"2019","unstructured":"Mangaraj S, Patro D, Choudhury AK, Baliarsinha AK. A rare case of acromegaly and autosomal dominant polycystic kidney disease: case report and brief review of literature. AACE Clin Case Rep. 2019;5(5):e302\u20136.","journal-title":"AACE Clin Case Rep"},{"issue":"1","key":"1013_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1507\/endocrj.EJ20-0173","volume":"68","author":"D Otani","year":"2021","unstructured":"Otani D, Murakami T, Matsubara T, Hojo M, Nakae T, Moriyoshi K, et al. Acromegaly accompanied by diabetes mellitus and polycystic kidney disease. Endocr J. 2021;68(1):103\u201310.","journal-title":"Endocr J"},{"issue":"4","key":"1013_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002777","volume":"16","author":"N Perico","year":"2019","unstructured":"Perico N, Ruggenenti P, Perna A, Caroli A, Trillini M, Sironi S, et al. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): a randomized, double-blind, placebo-controlled, multicenter trial. PLoS Med. 2019;16(4): e1002777.","journal-title":"PLoS Med"},{"issue":"19","key":"1013_CR22","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1001\/jama.2018.15870","volume":"320","author":"E Meijer","year":"2018","unstructured":"Meijer E, Visser FW, van Aerts RMM, Blijdorp CJ, Casteleijn NF, D\u2019Agnolo HMA, et al. Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial. JAMA. 2018;320(19):2010\u20139.","journal-title":"JAMA"},{"issue":"1","key":"1013_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-032620","volume":"10","author":"J Griffiths","year":"2020","unstructured":"Griffiths J, Mills MT, Ong AC. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis. BMJ Open. 2020;10(1): e032620.","journal-title":"BMJ Open"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01013-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-025-01013-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01013-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:05:02Z","timestamp":1758719102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-025-01013-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["1013"],"URL":"https:\/\/doi.org\/10.1007\/s13730-025-01013-1","relation":{},"ISSN":["2192-4449"],"issn-type":[{"type":"electronic","value":"2192-4449"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article contains no studies performed by authors with human participants or animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement"}},{"value":"Informed consent was obtained from this patient included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}